About AinsCorp
Established in 2008, AinsCorp Pty Ltd is an independent Australian owned company specialising in providing unique medical products that change people’s lives. AinsCorp operates in the Ostomy, Complex Wounds and Fistula medical device market, an area in which both the directors and employees have decades of experience. We have products sourced from around the world, each one selected with the aim to provide people with access to the highest quality medical products to suit individual needs. Our wide range of ostomy appliances are shipped from Salts Healthcare Ltd in the UK, where a focus lies in the production of superior hydrocolloids infused with aloe vera for the ultimate in skin care and protection.
In the area of complex wound care, we source our products from Fidia Pharma S.p.A. in Italy, a range of creams and ointments made from hyaluronic acid designed to create ideal conditions for accelerated wound recovery and skin regeneration. In Germany, our supplier for exceptional fistula devices is Phametra GmbH, a leading developer of progressive fistula care products.
At AinsCorp we promote and support both patients and medical professionals through education and training products that are unique and functionally superior in their features, clinical outcomes and cost effectiveness.
With representatives throughout Australia and New Zealand we are available five days a week from 9am to 5pm to provide extensive customer support both over the phone and via email.
In the area of complex wound care, we source our products from Fidia Pharma S.p.A. in Italy, a range of creams and ointments made from hyaluronic acid designed to create ideal conditions for accelerated wound recovery and skin regeneration. In Germany, our supplier for exceptional fistula devices is Phametra GmbH, a leading developer of progressive fistula care products.
At AinsCorp we promote and support both patients and medical professionals through education and training products that are unique and functionally superior in their features, clinical outcomes and cost effectiveness.
With representatives throughout Australia and New Zealand we are available five days a week from 9am to 5pm to provide extensive customer support both over the phone and via email.
Our Suppliers
LEARN MORE
Salts Healthcare is a British medical device manufacturer that delivers their products all around the world. At AinsCorp we distribute their superior ostomy products in both Australia and New Zealand. The relationship between these two companies has spanned 12 years and has seen consistent growth in sales in the region. Salts' devices have a clinically proven reputation for quality, innovation and cost effectiveness. Salts invest heavily in research and development, working with healthcare professionals to design and produce the highest quality devices.
Working with Salts Healthcare we attend ostomy conferences and set up trade displays across Australia and New Zealand. These events allows us to remain connected to our primary market and provide them with not only information on our newest products, but also answer any questions and provide solutions to complex issues. |
LEARN MORE
Hydrofera, LLC began operations in Essex, Connecticut, and Belleville, Illinois in 1996 as a division of Tolland Development Company, LLC. In 1997, the company consolidated operations in Willimantic, Connecticut to develop polyvinyl alcohol foam for health care markets.
Today Hydrofera is the developer of Hydrofera Blue Antibacterial Wound Dressings, an advanced line of wound care products designed to shorten healing times, lower treatment costs, and deliver better patient outcomes. |
LEARN MORE
Innovation is a key to strengthen Fidia's portfolio and a prerequisite for the success of our customers and partners.
Continually working to identify new treatment opportunities is the framework of our commitment to patients. High on the company's list of priorities is the study of hyaluronic acid, a molecule that at Fidia means tradition, innovation, excellence. By modifying its chemistry, new products and innovative drug delivery systems and technology platforms are formulated that consolidate Fidia's leadership in areas such as joint healthcare, advanced wound care and aesthetic dermatology. Fidia is continually working to identify new opportunities and develop an industry-leading pipeline of promising new treatments for specific pathologies in highly challenging areas, with products covered by international patents, that are a vital part of the company's heritage, as well as innovative formulations that will enhance their characteristics, without compromising the quality of care. |
